MannKind | MNKD - Fremdkapital





Fremdkapital Veränderung Datum
Adma Biologics USD 192.84M 745K 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Halozyme Therapeutics USD 1.94B 1.79M 2026-06
Insmed USD 543.51M 1.3M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
MannKind USD 545.13M 2.93M 2026-06
Merck USD 51.08B 4.41B 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Novavax USD 246.3M 200K 2025-12
Novo Nordisk DKK 18.61B 100.56B 2026-06
Pfizer USD 60.5B 70M 2026-06
Sanofi EUR 14.65B 806M 2026-06
Xencor USD 77.54M 4.59M 2026-06